Pharmagreen Biotech Inc. (PHBI)

Market Cap	1.20M +24.3%
Revenue (ttm)	3.00K -29.1%
Net Income	-226.26K
EPS	-0.00
Shares Out	691.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	461,707
Average Volume	648,711
Open	0.0017
Previous Close	0.0017
Day's Range	0.0016 - 0.0017
52-Week Range	0.0007 - 0.0035
Beta	1.77
RSI	42.88
Earnings Date	May 18, 2026

About Pharmagreen Biotech

Pharmagreen Biotech Inc. operates as a nutraceutical company, engages in the formulating products from blends of therapeutic plants and fungi in North America. The company’s primary product is MaxGenomic supplement, a proprietary blend and formulated medicinal mushrooms and medical plants to support the human mind and body. It also provides consulting services for plant genetic selection, tissue culture technologies for starter plantlets production, SOPs for cultivation and live storage of any plant species services. It sells its products throu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Peter Wojcik
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHBI

Financial Performance

In fiscal year 2024, Pharmagreen Biotech's revenue was $3,410, an increase of 13.74% compared to the previous year's $2,998. Losses were -$1.00 million, 76.6% more than in 2023.